JP6997620B2 - Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 - Google Patents

Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 Download PDF

Info

Publication number
JP6997620B2
JP6997620B2 JP2017529746A JP2017529746A JP6997620B2 JP 6997620 B2 JP6997620 B2 JP 6997620B2 JP 2017529746 A JP2017529746 A JP 2017529746A JP 2017529746 A JP2017529746 A JP 2017529746A JP 6997620 B2 JP6997620 B2 JP 6997620B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
sequence set
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537925A5 (en:Method
JP2017537925A (ja
Inventor
レニアー ジェイ． ブレントジェンズ，
エリック エル． スミス，
チェン リュー，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
ユーリカ セラピューティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, ユーリカ セラピューティックス， インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017537925A publication Critical patent/JP2017537925A/ja
Publication of JP2017537925A5 publication Critical patent/JP2017537925A5/ja
Application granted granted Critical
Publication of JP6997620B2 publication Critical patent/JP6997620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2017529746A 2014-12-05 2015-12-04 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 Active JP6997620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088309P 2014-12-05 2014-12-05
US62/088,309 2014-12-05
PCT/US2015/064112 WO2016090320A1 (en) 2014-12-05 2015-12-04 Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020075434A Division JP2020114254A (ja) 2014-12-05 2020-04-21 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用

Publications (3)

Publication Number Publication Date
JP2017537925A JP2017537925A (ja) 2017-12-21
JP2017537925A5 JP2017537925A5 (en:Method) 2019-01-17
JP6997620B2 true JP6997620B2 (ja) 2022-02-04

Family

ID=56092569

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017529746A Active JP6997620B2 (ja) 2014-12-05 2015-12-04 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
JP2020075434A Withdrawn JP2020114254A (ja) 2014-12-05 2020-04-21 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
JP2022077378A Pending JP2022105192A (ja) 2014-12-05 2022-05-10 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020075434A Withdrawn JP2020114254A (ja) 2014-12-05 2020-04-21 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
JP2022077378A Pending JP2022105192A (ja) 2014-12-05 2022-05-10 Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用

Country Status (21)

Country Link
US (5) US10918665B2 (en:Method)
EP (2) EP3227432B1 (en:Method)
JP (3) JP6997620B2 (en:Method)
KR (2) KR102698738B1 (en:Method)
CN (3) CN107208047B (en:Method)
AU (2) AU2015357526B2 (en:Method)
CA (1) CA2969870A1 (en:Method)
DK (1) DK3227432T3 (en:Method)
ES (1) ES2966099T3 (en:Method)
FI (1) FI3227432T3 (en:Method)
IL (2) IL295298A (en:Method)
MX (2) MX2017007244A (en:Method)
MY (1) MY191537A (en:Method)
NZ (1) NZ732563A (en:Method)
PH (1) PH12017501040B1 (en:Method)
PL (1) PL3227432T3 (en:Method)
PT (1) PT3227432T (en:Method)
RU (1) RU2761632C2 (en:Method)
SA (1) SA517381666B1 (en:Method)
SG (2) SG10201900931XA (en:Method)
WO (1) WO2016090320A1 (en:Method)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2888349B1 (en) 2012-08-24 2022-02-09 Yale University System, device and method for high-throughput multi-plexed detection
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EP3227684B1 (en) 2014-12-03 2019-10-02 Isoplexis Corporation Analysis and screening of cell secretion profiles
CN109072199B (zh) * 2014-12-05 2022-10-28 纪念斯隆-凯特琳癌症中心 靶向Fc受体样5的嵌合抗原受体及其用途
CA2969870A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
AU2015357533B2 (en) 2014-12-05 2021-10-07 Eureka Therapeutics, Inc. Antibodies targeting B-cell maturation antigen and methods of use
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
PE20171653A1 (es) 2015-04-13 2017-11-13 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3402515B8 (en) 2016-01-12 2021-12-08 Oncotracker, Inc. Improved methods for monitoring immune status of a subject
PE20190120A1 (es) 2016-04-01 2019-01-17 Kite Pharma Inc Moleculas de union a bcma y metodos de uso de las mismas
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20200166518A1 (en) 2016-09-12 2020-05-28 IsoPlexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
EP3538891B1 (en) 2016-11-11 2022-01-05 Isoplexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3545284A4 (en) 2016-11-22 2020-07-01 Isoplexis Corporation SYSTEMS, DEVICES AND METHODS FOR CAPTURING CELLS AND MANUFACTURING METHODS THEREOF
AU2017384900B2 (en) 2016-12-28 2020-12-10 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP2020517287A (ja) 2017-04-26 2020-06-18 ユーリカ セラピューティックス， インコーポレイテッド キメラ抗体／ｔ細胞受容体構築物及びその使用
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3618842B1 (en) 2017-05-01 2023-10-18 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110914289B (zh) 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
BR112020001605A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos para produzir composições de células geneticamente modificadas e composições relacionadas
MA49981A (fr) 2017-08-09 2020-06-17 Juno Therapeutics Inc Procédés et compositions de préparation de cellules génétiquement modifiées
EP3679370A1 (en) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN111108125A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
CN107827989A (zh) * 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CA3080904A1 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN107557342A (zh) * 2017-11-02 2018-01-09 广东万海细胞生物科技有限公司 一种CAR‑Treg 细胞的制备方法及其应用
JP7233425B2 (ja) 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
CA3082570A1 (en) 2017-11-14 2019-05-23 Memorial Sloan-Kettering Cancer Center Il-36 secreting immunoresponsive cells and uses thereof
WO2019098682A1 (ko) 2017-11-14 2019-05-23 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
MX2020005908A (es) 2017-12-08 2020-10-07 Juno Therapeutics Inc Proceso para producir una composicion de celulas t modificadas.
MA51105A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
PL3674328T3 (pl) * 2018-02-01 2024-09-16 Nanjing IASO Biotechnology Co., Ltd. Chimeryczny receptor antygenu (car) wiążący się z bcma i jego zastosowania
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3781177A4 (en) * 2018-04-19 2022-03-02 Baylor College of Medicine REPROGRAMMING OF CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8AB AND CLASS 1 RESTRICTED T CELL RECEPTORS
BR112020022879A2 (pt) 2018-05-11 2021-02-23 Crispr Therapeutics Ag métodos e composições para tratamento de câncer
EP3801551A4 (en) 2018-05-24 2022-04-06 Ayala Pharmaceuticals Inc. COMPOSITIONS WITH BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTICS AND METHODS OF USE THEREOF
CA3100724A1 (en) * 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
CN119954969A (zh) 2018-07-19 2025-05-09 瑞泽恩制药公司 具有bcma特异性的嵌合抗原受体及其用途
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
BR112021002245A2 (pt) 2018-08-09 2021-05-04 Juno Therapeutics Inc métodos para avaliar ácidos nucleicos integrados
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
HRP20251135T1 (hr) 2018-08-31 2025-11-21 Novartis Ag Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020057668A1 (zh) * 2018-09-21 2020-03-26 科济生物医药（上海）有限公司 基于CRISPR/Cas系统对细胞进行基因编辑的方法
ES2927220T3 (es) 2018-10-01 2022-11-03 Caribou Biosciences Inc Composiciones y procedimientos de módulos suicidas
CN112805302B (zh) * 2018-10-10 2023-01-31 深圳华大生命科学研究院 抗BCMA单链抗体scFv及其制备方法和应用
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
EP3874272A1 (en) 2018-10-31 2021-09-08 GlaxoSmithKline Intellectual Property Development Limited Methods of treating cancer
WO2020092848A2 (en) * 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
MX2021006238A (es) 2018-11-30 2021-10-01 Juno Therapeutics Inc Metodos para tratamiento que usan terapia celular adoptiva.
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202109024YA (en) 2019-04-12 2021-09-29 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
MX2021013351A (es) * 2019-04-30 2022-01-31 Memorial Sloan Kettering Cancer Center Terapias de combinacion.
MX2021013219A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
JP2022537700A (ja) 2019-06-12 2022-08-29 ジュノー セラピューティクス インコーポレイテッド 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
CA3146471A1 (en) 2019-08-06 2021-02-11 James K. Kranz Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021154887A1 (en) 2020-01-28 2021-08-05 Juno Therapeutics, Inc. Methods for t cell transduction
JP2023519099A (ja) 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
CN116157125A (zh) 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
IL307598A (en) 2021-04-16 2023-12-01 Juno Therapeutics Inc T-cell therapy in patients who have had a previous stem cell transplant
JP2024514163A (ja) 2021-04-16 2024-03-28 セルジーン コーポレーション Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
US20250319185A1 (en) * 2021-07-12 2025-10-16 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
CA3229746A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
JP2024540320A (ja) 2021-11-03 2024-10-31 セルジーン コーポレーション 骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
JP2025503949A (ja) 2022-01-25 2025-02-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンに対する併用療法
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
IL316839A (en) 2022-05-17 2025-01-01 Umoja Biopharma Inc Production of viral particles
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
JP2025524373A (ja) 2022-06-10 2025-07-30 ウモジャ バイオファーマ インコーポレイテッド 操作された幹細胞およびその使用
CA3263560A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
EP4626476A1 (en) * 2022-12-02 2025-10-08 Artiva Biotherapeutics, Inc. Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2024121711A1 (en) 2022-12-05 2024-06-13 Glaxosmithkline Intellectual Property Development Limited Methods of treatment using b-cell maturation antigen antagonists
EP4630782A1 (en) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GEP20053685B (en) 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CN101460518B (zh) 2006-06-06 2012-08-22 克鲁塞尔荷兰公司 针对肠球菌和金黄色葡萄球菌具有杀伤活性的人结合分子及其应用
SI2132230T1 (sl) * 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
HRP20190556T1 (hr) 2009-11-03 2019-06-14 City Of Hope SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
JP2011178691A (ja) 2010-02-26 2011-09-15 Takuya Ueda カテニン結合プローブとその用途
EP2640750A1 (en) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
SI2961831T1 (sl) 2013-02-26 2020-10-30 Memorial Sloan Kettering Cancer Center Sestavki in postopki za imunoterapijo
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10316101B2 (en) 2014-04-14 2019-06-11 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
CA2969870A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
AU2015357533B2 (en) 2014-12-05 2021-10-07 Eureka Therapeutics, Inc. Antibodies targeting B-cell maturation antigen and methods of use
RS62527B1 (sr) 2014-12-12 2021-11-30 2Seventy Bio Inc Bcma receptori himernog antigena
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen

Also Published As

Publication number Publication date
FI3227432T3 (fi) 2024-01-09
EP3227432B1 (en) 2023-10-11
PH12017501040A1 (en) 2018-03-05
US20200276239A1 (en) 2020-09-03
KR20240130831A (ko) 2024-08-29
ES2966099T3 (es) 2024-04-18
AU2015357526B2 (en) 2022-03-17
CN107208047B (zh) 2021-09-21
AU2015357526A1 (en) 2017-06-29
RU2017123548A3 (en:Method) 2019-07-17
BR112017011909A2 (pt) 2018-02-27
JP2022105192A (ja) 2022-07-12
KR102698738B1 (ko) 2024-08-28
US20200276240A1 (en) 2020-09-03
US10918665B2 (en) 2021-02-16
RU2761632C2 (ru) 2021-12-13
SA517381666B1 (ar) 2022-07-28
RU2017123548A (ru) 2019-01-14
MX2022001293A (es) 2022-02-22
EP4310097A2 (en) 2024-01-24
CN113603795A (zh) 2021-11-05
EP4310097A3 (en) 2024-04-03
US20180360880A1 (en) 2018-12-20
MY191537A (en) 2022-06-30
CN113698497A (zh) 2021-11-26
US11000549B2 (en) 2021-05-11
WO2016090320A1 (en) 2016-06-09
IL295298A (en) 2022-10-01
SG10201900931XA (en) 2019-02-27
KR20170109538A (ko) 2017-09-29
EP3227432A4 (en) 2018-08-22
EP3227432A1 (en) 2017-10-11
DK3227432T3 (en) 2023-10-23
JP2020114254A (ja) 2020-07-30
CA2969870A1 (en) 2016-06-09
PT3227432T (pt) 2023-12-06
PH12017501040B1 (en) 2023-07-05
CN107208047A (zh) 2017-09-26
US20240335475A1 (en) 2024-10-10
JP2017537925A (ja) 2017-12-21
SG11201704549UA (en) 2017-07-28
AU2022204181A1 (en) 2022-07-07
MX2017007244A (es) 2018-01-25
IL252617A0 (en) 2017-07-31
PL3227432T3 (pl) 2024-03-11
IL252617B (en) 2022-09-01
US20210346432A1 (en) 2021-11-11
NZ732563A (en) 2023-01-27
US10821135B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
JP6997620B2 (ja) Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
US12139538B2 (en) Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
US10906956B2 (en) Methods of treatments using chimeric antigen receptors targeting G-protein coupled receptor
BR112017011909B1 (pt) Receptor de antígeno quimérico (car), molécula de ácido nucleico, vetor, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar um tumor
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20210215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211217

R150 Certificate of patent or registration of utility model

Ref document number: 6997620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250